[
    [
        {
            "time": "",
            "original_text": "【招商医药吴斌团队】医药生物行业2019年半年报回顾--政策影响趋于缓和，疫苗等子板块维持高景气",
            "features": {
                "keywords": [
                    "医药生物",
                    "2019年半年报",
                    "政策影响",
                    "缓和",
                    "疫苗",
                    "高景气"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 9,
                "Entity_Density": 5,
                "Market_Scope": 10,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        }
    ]
]